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INTRODUCTION
The factors that regulate the cell-matrix interactions are
essential for invasiveness and metastatic behavior. Proteinases
that are expressed by epithelial cells, such as cathepsins, metal-
loproteinases and serine proteinases, are able to degrade the ex-
tracellular matrix and so they may facilitate tumor invasion (1).
Maspin is a relatively novel member of the serine proteinase
inhibitor (serpin) family; it plays a role in the development
of the mammary gland (2) and it shows positive expression
on myoepithelial cells and normal secretory epithelial cells (3).
In vitro and animal models have shown that maspin inhibits
tumorigenesis, which consists of tumor cell growth, invasion
and metastasis (3, 4). Zhang et al. (5) reported that maspin
also inhibits endothelial cell motility and angiogenesis, and
they provided possible evidence of a maspin-tumor suppres-
sor mechanism. 
Although the precise molecular and biologic mechanisms
of maspin remain unknown, there is an evidence that maspin
interacts with the p53 tumor suppressor pathway and it may
function as an inhibitor of angiogenesis in vitro and in vivo
(5, 6). Zou et al. (6) reported that p53 regulates the expression
of maspin, and that its expression can be induced by DNA
damage in cells containing the wild-type p53. However, to
date, the exact tumor suppressor mechanism of maspin, as
related with p53, remains unknown. 
There is very limited data on the clinical significances of
maspin expression in human breast cancer. There has been
one report investigating the prognostic significance of the
maspin expression in a large series involving breast cancer
patients with long-term follow-up (7). The prognostic utility
of maspin currently remains controversial (8-10). 
The aim of this study was to investigate the role of maspin
in tumorigenesis and tumor progression, and we wanted to
determine its potential as a new prognostic factor for breast
carcinomas. We tried to assess the maspin expression in inva-
sive ductal carcinoma (IDC). By comparing with the clini-
copathologic variables (age, histologic grade, tumor size, and
lymph node status), the estrogen receptor (ER), progesterone
receptor (PR) and p53 expression, and DNA ploidy, we attem-
pted to determine the clinicopathological significance of mas-
pin expressions in breast carcinomas. Furthermore, we exam-
ined the prognostic value of maspin expression by establish-
ing its correlation with the survival rates of the patients. 
MATERIALS AND METHODS 
Materials 
Eighty patients with IDC of the breast who were operated
on at our hospital between 1991 and 1996 were considered
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Clinicopathological Significance of Maspin Expression in Breast Cancer
Maspin is a unique serine proteinase inhibitor that has tumor suppressor activity. It
has been reported that maspin is expressed in normal human mammary epithelial
cells and it is down-regulated during the progression of cancer. However, to date,
there is very limited data on the clinical significance of maspin expression in human
breast cancer. In this study, maspin expression was assessed immunohistochemi-
cally from 80 invasive ductal carcinoma (IDC) specimens of the breast. Also, maspin
expression was compared with the clinicopathological factors (age, grade, tumor
size and lymph node status), the expression of estrogen receptor (ER), progesterone
receptor (PR) and p53, DNA ploidy and the overall survival in an attempt to assess
its prognostic value. The maspin expression was positive in 25 IDC cases (31.3%).
The maspin expression in IDC was significantly correlated with a higher histologic
grade, a larger tumor size, a positive p53 status and shorter survival. There was an
inverse association with maspin expression and the PR status. These findings sug-
gest that maspin expression is not down-regulated with the progression of cancer
and maspin expression may be associated with a poor prognosis. The immunohis-
tochemical detection of maspin in breast cancers may be helpful for predicting an
aggressive phenotype.
Key Words : Serpins; Immunohistochemistry; Prognosis; Breast Neoplasms
Received : 18 March 2005
Accepted : 16 September 2005310 M.-J. Lee, C.-H. Suh, Z.-h. Li
for analysis. We excluded those breast tissues from patients
who had no follow up and if they had undergone chemother-
apy or radiation therapy prior to surgery. The patients had
undergone either a mastectomy or breast-conserving surgery
with axillary lymph node (LN) dissection. The patients who
underwent mastectomy had received adjuvant chemotherapy
and hormonal therapy. The patients who underwent breast-
conserving surgery had received adjuvant radiation therapy
and hormonal therapy. By reviewing the medical records and
the pathological reports of the selected patients, we summa-
rized the patient's age, tumor size and lymph node status. We
determined the survival rates for the 80 IDC patients. The
patients were followed up for 11-115 months (median 63
months) postoperatively. 
Pathological classification 
The histologic grades of the invasive ductal carcinomas were
determined according to the Nottingham modification of the
Bloom-Richardson system (11). According to the TNM clas-
sification, the primary tumor sizes were divided into tumors
smaller than 2.0 cm (T1), tumors between 2.1 to 5.0 cm (T2)
and tumors larger than 5.0 cm (T3). Lymph node involve-
ment was divided into no metastasis and metastasis. 
Immunohistochemistry 
Tissue sections were prepared as 4  m-thick-slides from the
paraffin-embedded specimens; they were deparaffinized with
xylene, rehydrated with alcohol and washed with distilled wa-
ter. For antigen retrieval, the slides were immersed in citrate
buffer solution (10 mM, pH 6.0) and microwaved for 10 min
at 99℃ (900 W), and then they were cooled and washed in
Tris buffer solution (TBS). The endogenous peroxidase activi-
ty was blocked with 3% hydrogen peroxide. They were react-
ed with primary antibodies and allowed to incubate over-
night at 4℃. The primary antibodies were monoclonal anti-
bodies for maspin (EAW24, 1:20, NeoMarkers, Fremont,
CA, U.S.A.), ER (ER-1D5, 1:50, Immunotech, Westbrook,
ME, U.S.A.), PR (clone 1A6, 1:50, Immunotech) and p53
(DO-7, 1:50, NeoMarkers). This was followed by using a
Picture
TM Plus kit (a polymer detection system, Zymed, South
San Francisco, CA, U.S.A.). AEC (3-amino-9-ethyl carbazole)
solution was applied as the chromogen and the nuclei were
counterstained with hematoxylin. For the positive control of
each antibody, prostate tissues were used for maspin and breast
carcinoma tissues that had been previously identified as being
positive were used for ER, PR, and p53. 
Evaluation 
The positivity for each antibody was determined as a defi-
nite positive reaction in the cytoplasm or cytoplasm and nu-
cleus for maspin, and a definite positive reaction in the nucle-
us for each ER, PR, and p53 protein. The results were deter-
mined as negative for each antibody if less than 10% stain-
ing was noted, and the results were positive if more than 10%
staining was noted. 
Analysis of DNA ploidy
For the DNA index analysis, two or three serial paraffin
sections were prepared at 50  m-thickness; they were deparaf-
finized with xylene, rehydrated with alcohol and washed with
PBS (phosphate buffered saline solution). The tissue sections
were minced to a single cell suspension in DMSO buffer (di-
methylsulfoxide in sucrose sodium citrate buffer). 2×10
6 cells
were washed twice with PBS. The cells were reacted with
solution A (trypsin in spermine tetrahydrochloride detergent
buffer, CycleTEST
TM Plus Reagent Kit, Becton-Dickinson,
Franklin Lakes, NJ, U.S.A.) for 10 min at room temperature.
After treatment with solution B (RNase A and trypsin inhi-
bitor in spermine buffer) for 10 min at room temperature,
the cells were stained with solution C (propidium iodide in
spermine buffer). The DNA index analysis was determined
by a FACSCalibur (Becton-Dickinson) and with using human
lymphocyte nuclei as the controls. 
Statistical analysis 
Pearson chi square tests were used to evaluate the relation-
ship among the patients age, histological grade, tumor size,
lymph node status, DNA ploidy and expressions of maspin,
ER, PR and p53. Univariate survival analyses were carried
out using log-rank tests. Multivariate survival analyses were
carried out according to the Cox regression model. Signifi-
cance was determined as p value less than 0.05. All statisti-
cal analyses were performed using the SPSS program (version
12.0). 
RESULTS
Expressions of maspin, ER, PR and p53
The maspin expression showed strong nuclear reactivity
and weak cytoplasmic reactivity on the myoepithelial cells
in the normal gland neighboring the ductal carcinoma in situ
(DCIS) (Fig. 1) and in the IDC (Fig. 2). No positive staining
was observed in the epithelial cells. However, in the cancer
cells, the maspin was expressed in the cytoplasm. Some cells
also exhibited maspin nuclear staining that accompanied the
cytoplasmic staining (Fig. 3). The maspin expression was posi-
tive in 25 IDC cases (31.3%). The expressions of ER, PR and
p53 in the IDC tissues were positive in 42 cases (52.5%), 37
cases (46.3%), and 26 cases (32.5%), respectively.Maspin Expression in Breast Cancer 311
Correlation between maspin positivity and the 
clinicopathological variables
When the maspin expression was compared with the clin-
icopathological variables, the maspin expression showed a
significant association with the higher histologic grade (p=
0.005) and the larger tumor size (p=0.02) (Table 1).
Correlation between maspin expression and expression
of ER, PR and p53, and DNA ploidy 
There was a significant inverse relationship between the
maspin and PR expressions (p=0.001). In other words, while
the PR was positive, the maspin was negative and when the
PR was negative, the maspin was positive. Also, a significant
Total
Maspin expression
Positive Negative
p value
Cases 80 25 55
Age (yr) 0.95
≤39 15 5 10
40-49 29 10 19
50-59 25 7 18
≥60 11 3 8
Grade 0.005
I1 8 1 1 7
II 37 11 26
III 25 13 12
Tumor size (cm) 0.02
≤2.0 19 2 17
2.1-5.0 51 17 34
>5.0 10 6 4
Lymph nodes 0.695
Negative 41 12 29
Positive 39 13 26
Table 1. Correlation between maspin positivity and clinicopatho-
logical variables in invasive ductal carcinoma of breast
Fig. 1. The maspin expression shows strong nuclear reactivity and
weak cytoplasmic reactivity on the myoepithelial cells of ductal car-
cinoma in situ and remaining glands. The epithelial cells are neg-
atively stained (Anti-maspin, ×200). 
Fig. 2. Immunonegativity for maspin is seen in invasive ductal car-
cinoma, but strong positivity in myoepithelial cells of the remaining
glands (Anti-maspin, ×200).
Fig. 3. The maspin is expressed in the cytoplasm of the cancer
cells. Some cells shows nuclear staining that accompanied the
cytoplasmic staining (Anti-maspin, ×400). association was noted between the maspin and p53 expres-
sions in the IDC tissue (p=0.046) (Table 2). 
Correlation between the survival rate and the variables 
Eighty IDC patients were followed up for at least five years,
and their survival rate was 61.3%. Univariate analysis showed
a significant difference in the overall survival according to the
histologic grade (p=0.01), tumor size (p=0.04), the lymph
node status (p=0.0001), the ER status (p=0.02), the PR sta-
tus (p<0.00001), the p53 status (p=0.003) and the maspin
expression (p=0.007) (Fig. 4). Age and DNA ploidy showed
no significant difference for the overall survival. From the Cox
multivariate analyses, the histologic grade (p=0.006), tumor
size (p=0.01), positive nodes (p=0.0003), the expressions of
ER (p=0.03), PR (p=0.0001), maspin (p=0.01), and p53 (p=
0.005) were prognostically significant (Table 3). 
DISCUSSION
Proteinases and their inhibitors are known to play impor-
tant roles in tumor invasion and metastasis. Two classes of
proteinases have been extensively studied in breast cancer and
other cancers; serine proteinase and their inhibitors (plasmino-
gen activator inhibitors, PAI) and the metalloproteinases and
the tissue inhibitors of metalloproteinases (12, 13). As a mem-
ber of the serpin superfamily, maspin (mammary serpin) is a
novel proteinase inhibitor that is related to other inhibitors
such as PAI (13). 
Since the first report by Zou et al. (3) revealed the loss of
maspin expression in advanced cancers with using immuno-
histochemistry (IHC), there had been a few reports investi-
gating the clinical significance of maspin expression by per-
forming IHC. Hojo et al. (14) have found that maspin-posi-
tive breast cancer showed a low pathologic grade of malignan-
cy. However, in their study, the sample number was small
(n=49) and any correlation with the clinical outcome was not
investigated. Maass et al. (15) have reported that the down-
regulation of the maspin gene in breast carcinoma was asso-
ciated with a higher risk of distant metastasis by using RT-
PCR. However, since the mammary myoepithelial cells sur-
rounding the normal ducts and the noninvasive ductal com-
ponents express the maspin protein (16), it could be difficult
to evaluate the “maspin expression in breast carcinoma” by
means of employing RT-PCR methods. Maass et al. (17) have
recently suggested that the decline in the expression of maspin
was associated with tumor progression in ductal carcinomas
of the breast with using 12 cases of DCIS, 128 cases of IDC
and their lymph node metastases. However, in their study,
there was a weak inverse association with the PR status and
the number of DCIS cases was small (n=12). 
Their findings strongly contrast with ours. We demonstrat-
ed that the expression of maspin, as detected by IHC, was
significantly correlated with an aggressive phenotype that
was characterized by a higher histologic grade, a larger tumor
size and a negative PR status in the breast carcinoma tissues.
The univariate analysis via the log-rank test clearly indicated
a strong correlation between the expression of maspin and a
shorter overall survival. Moreover, the multivariate analysis
that included such known prognostic factors as tumor size,
histologic grade, hormone receptor and p53 status showed
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Fig. 4. Univariate analysis of 80 patients of invasive ductal carcino-
ma shows a significant difference in the overall survival according
to the maspin expression.
MASPIN
Expression
No expression
Total
Maspin expression
Positive Negative
p value
ER Positive 42 11 31 0.30
Negative 38 14 24
PR Positive 37 5 32 0.001
Negative 43 20 23
p53 Positive 26 12 14 0.046
Negative 54 13 41
DNA Ploidy 0.398
Dipoidy 68 20 48
Aneuploidy 12 5 7
Table 2. Correlation between maspin expression and expression
of ER, PR and p53, and DNA ploidy in invasive breast cancer
Variables p value RR 95% CI
Age 0.56 1.12 0.77-1.62
Histologic grade 0.006 2.12 0.24-3.64
Tumor size 0.01 2.13 1.14-3.98
Positive nodes 0.0003 4.50 1.99-10.15
ER 0.03 0.44 0.21-0.92
PR 0.0001 0.14 0.06-0.37
Maspin 0.01 2.52 1.25-5.12
p53 0.005 2.72 1.34-5.52
Aneuploidy 0.25 1.69 0.69-4.13
Table 3. Cox multivariate analysis of overall survival in invasive
breast cancer
RR, relative risk; 95% CI, 95% confidence interval.that the expression of maspin was an independent indicator
of a poor prognosis. These findings seemed to be contrary to
the expected results that the loss of maspin expression would
correlate with a poor prognosis if the expression of maspin
was down-regulated during the progression of breast cancer. 
A recent studies showed that the expression of maspin was
correlated with an aggressive phenotype in the breast cancer
(7, 8), pancreatic cancer (18) and ovarian cancer (19). Also, the
maspin expression was significantly associated with a shorter
relapse-free survival and a shorter overall survival (7). Umekita
et al. (7) results were similar with ours. The association bet-
ween the maspin expression level and the survival rate has
not been demonstrated in human cancer except in the reports
by Umekita et al. (7) and Xia et al. (20). Umekita et al. (8)
suggested three possible explanations for the aberrant expres-
sion of maspin in breast cancer cells. One was the mutation
of the maspin gene, the second was a high intracellular con-
centration of maspin resulting in auto-inhibition of its activi-
ty. The third was that myoepithelial cell differentiation in
carcinoma cells could contribute to the more aggressive phe-
notype. We think that the mutation of the maspin gene caus-
es the loss of normal function of the maspin protein. There-
fore, mutational analyses with using maspin-positive samples
are needed to resolve this issue. 
Maspin expression has always regarded to be limited to the
cytoplasmic compartment of the cell. However the presence
of maspin in both the nuclear and cytoplasmic compartments
has been shown by Pemberton et al. (21) with using cell frac-
tions and Western blotting, and by Chu et al. (22) with using
IHC. One possible explanation for the detection of signals
from both nucleus and cytoplasm with using IHC is the anti-
gen retrieval technique; this might have exhibited a cross-
reacting epitope in the nucleus. Mohsin et al. (9) reported
that maspin nuclear staining was significantly associated with
good prognostic factors, while cytoplasmic staining was asso-
ciated with poor prognostic markers. However, the function
and significance of this pattern of expression is currently un-
known. In our study, the staining in normal breast tissue (this
was present in some areas of the tumor) showed a strong nu-
clear and weak cytoplasmic staining in the myoepithelial cells,
but there was cytoplasmic staining or cytoplasmic and nucle-
ar staining in the tumor cells. We decided to evaluate the
maspin expression in the cytoplasm or the cytoplasm and
nuclei of breast cancer cells. 
The mechanism underlying the function of maspin as a
tumor suppressor is not fully understood. Hojo et al. (14) re-
ported that the maspin positive group of tumors had a ten-
dency to stain less strongly for p53 protein in the tumor sec-
tions. They considered that maspin can be upregulated by
promotor activation through p53 directly binding to the p53
consensus binding site in the maspin promotor, but the p53
binding site was refractory to mutant p53. Zhang et al. (23)
indicated that in most tumors mutant p53 is inversely cor-
related with maspin expression, and this suggests maspin is
likely a p53 target gene in vivo. Our study and Umekita et al.
(7) revealed a significant correlation between the expression
of maspin and the p53 protein in breast cancer by performing
IHC. Although our data cannot definitely prove this function-
al correlation between both proteins, it may provide addition-
al information on a p53 dependent regulatory pathway of the
maspin protein in breast cancer. 
Although a larger series and longer follow-up are needed,
our present investigation suggests that the expression of mas-
pin could be an independent poor prognostic indicator for
breast cancer patients. Further investigation are needed to
clarify the precise mechanism of the aberrant expression of
maspin in the breast cancer that has an aggressive phenotype.
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